{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:20:50Z","timestamp":1778901650712,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Cure SMA Industry Collaboration"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.clinthera.2019.03.012","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:57:49Z","timestamp":1556845069000},"page":"943-960.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community"],"prefix":"10.1016","volume":"41","author":[{"given":"Ros\u00e1ngel","family":"Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Belter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Wasnock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al","family":"Nazarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.03.012_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","author":"McGraw","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","article-title":"Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study","volume":"15","author":"Qian","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2019.03.012_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2019.03.012_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clinthera.2019.03.012_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/GIM.0b013e318188d069","article-title":"Carrier screening for spinal muscular atrophy","volume":"10","author":"Prior","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2019.03.012_bib7","doi-asserted-by":"crossref","first-page":"822e826","DOI":"10.1080\/13696998.2016.1198355","article-title":"The economic burden of spinal muscular atrophy","volume":"19","author":"Armstrong","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2019.03.012_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JND-170292","article-title":"An overview of the Cure SMA membership database: highlights of key demographic and clinical characteristics of SMA members","volume":"5","author":"Belter","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2019.03.012_bib9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2017.02.014","article-title":"218th ENMC International Workshop. Revisiting the consensus on standards of care in spinal muscular atrophy","author":"Finkel","year":"2017","journal-title":"J Neuromusc Dis"},{"key":"10.1016\/j.clinthera.2019.03.012_bib10","unstructured":"FDA News Release. FDA approves first drug for spinal muscular atrophy. 12.23.16.https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm534611.htm."},{"key":"10.1016\/j.clinthera.2019.03.012_bib11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2019.03.012_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2019.03.012_bib13","series-title":"The Voice of the Patient Report for Spinal Muscular Atrophy","author":"Cure","year":"2018"},{"key":"10.1016\/j.clinthera.2019.03.012_bib14","unstructured":"About Cure SMA. http:\/\/www.curesma.org\/about\/."},{"key":"10.1016\/j.clinthera.2019.03.012_bib15","series-title":"Results from the Cure SMA Newly Diagnosed Survey. Poster presented at American Academy of Neurology 2018 Annual Conference","author":"Belter","year":"2018"},{"key":"10.1016\/j.clinthera.2019.03.012_bib16","series-title":"Externally-Led Patient Focused Drug Development Meetings","author":"FDA Guidance (PDUFA)","year":"2015"},{"key":"10.1016\/j.clinthera.2019.03.012_bib18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","article-title":"Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients","volume":"27","author":"Rouault","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2019.03.012_bib19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2016.04.008","article-title":"Patient preferences in regulatory benefit-risk assessments: a US perspective","volume":"19","author":"Johnson","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.03.012_bib20","unstructured":"Cure SMA. 2018 Updated SMA Drug Pipeline Released. http:\/\/www.curesma.org\/news\/2018-sma-drug-pipeline.html."},{"key":"10.1016\/j.clinthera.2019.03.012_bib21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40273-016-0429-5","article-title":"Using best-worst scaling to investigate preferences in health care","volume":"34","author":"Cheung","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2019.03.012_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-016-0444-9","article-title":"Quantifying benefit risk preferences for new medicines in rare disease patients and caregivers","volume":"11","author":"Morel","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2019.03.012_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/mus.25411","article-title":"Patient-centered benefit-risk assessment in Duchenne muscular dystrophy","volume":"55","author":"Hollin","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2019.03.012_bib24","unstructured":"Key Considerations in Developing & Integrating Patient Perspectives in Drug Development: Examination of the Duchenne Case Study. https:\/\/www.bio.org\/sites\/default\/files\/BIO_PPMD_whitepaper_web.pdf."},{"key":"10.1016\/j.clinthera.2019.03.012_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jmg.15.6.409","article-title":"Incidence, prevalence, and gene frequency studies of chronic childhood muscular atrophy","volume":"15","author":"Pearn","year":"1978","journal-title":"J Med Genet"},{"key":"10.1016\/j.clinthera.2019.03.012_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2019.03.012_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/WCO.0b013e32833e1765","article-title":"The genetics of spinal muscular atrophies","volume":"23","author":"Wee","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib28","article-title":"Primary efficacy and safety results from the Phase 3 ENDEAR study of nusinersen in infants diagnosed with spinal muscular atrophy (SMA)","volume":"vols. 11\u201313","author":"Finkel","year":"2017"},{"key":"10.1016\/j.clinthera.2019.03.012_bib29","year":"2016"},{"key":"10.1016\/j.clinthera.2019.03.012_bib30","series-title":"Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.clinthera.2019.03.012_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1370\/afm.1937","article-title":"Using best-worst scaling to understand patient priorities: a case example of Papanicolaou tests for homeless women","volume":"14","author":"Wittenberg","year":"2016","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.clinthera.2019.03.012_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2019.03.012_bib33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2019.03.012_bib34","series-title":"Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe, TREAT-NMD and European Medicines Agency Meeting","author":"SMA Europe and TREAT-NMD","year":"2016"},{"key":"10.1016\/j.clinthera.2019.03.012_bib35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1086\/302369","article-title":"Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype phenotype correlation, and implications for genetic counseling","volume":"64","author":"Wirth","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2019.03.012_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet"},{"key":"10.1016\/j.clinthera.2019.03.012_bib38","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4","volume":"88","author":"Wadman","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2019.03.012_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clinthera.2019.03.012_bib41","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2019.03.012_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy. Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2019.03.012_bib43a","unstructured":"US FDA. US FDA. Benefit-Risk Assessment in Drug Regulatory Decision-Making: Draft PDUFA VI Implementation Plan (FY 2018-2022), https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM329758.pdf."},{"key":"10.1016\/j.clinthera.2019.03.012_bib44b","unstructured":"Draft PDUFA V Implementation Plan - February 2013 Fiscal Years 2013-2017. https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM602885.pdf."},{"issue":"5e6 Suppl A","key":"10.1016\/j.clinthera.2019.03.012_bib45","first-page":"4Se19S","article-title":"Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials","volume":"10","author":"Keefe","year":"2013","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.clinthera.2019.03.012_bib46","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1378\/chest.09-2144","article-title":"Extubation of patients with neuromuscular weakness: a new management paradigm","volume":"137","author":"Bach","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2019.03.012_bib47","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type 1","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2019.03.012_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib49","article-title":"Benefit-risk assessments in rare disorders: the case for therapeutic development in duchenne muscular dystrophy as the prototype for new approaches","author":"Franson","year":"2013","journal-title":"PPMD Whitepaper"},{"key":"10.1016\/j.clinthera.2019.03.012_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/11539660-000000000-00000","article-title":"Using best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia","volume":"3","author":"Louviere","year":"2010","journal-title":"The Patient"},{"key":"10.1016\/j.clinthera.2019.03.012_bib51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10897-015-9872-2","article-title":"Prioritizing parental worry associated with Duchenne muscular dystrophy using best-worst scaling","volume":"25","author":"Peay","year":"2016","journal-title":"J Genet Counsel"},{"key":"10.1016\/j.clinthera.2019.03.012_bib52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1176\/appi.ps.201300525","article-title":"A best-worst scaling experiment to prioritize caregiver concerns with attention deficit\/hyperactivity disorder (ADHD) medicine for children","volume":"66","author":"Ross","year":"2015","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2019.03.012_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","article-title":"Best-worst scaling: what it can do for the health care research and how to do it","volume":"26","author":"Flynn","year":"2007","journal-title":"J Health Econ"},{"key":"10.1016\/j.clinthera.2019.03.012_bib54","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/risa.12012","article-title":"Investigating heterogeneity in the characterization of risks using best-worst scaling","volume":"33","author":"Erdem","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.clinthera.2019.03.012_bib55","series-title":"State of the Science: Methods to Collect and Use Patient Preference Data","author":"US Food & Drug Administration Center for Devices and Radiologic Health Workshop","year":"2013"},{"key":"10.1016\/j.clinthera.2019.03.012_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1740774513512726","article-title":"Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne\/Becker muscular dystrophy","volume":"11","author":"Peay","year":"2014","journal-title":"Clin Trials"},{"key":"10.1016\/j.clinthera.2019.03.012_bib57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ijporl.2009.07.009","article-title":"Parent versus child assessment of quality of life in children using cochlear implants","volume":"73","author":"Warner-Czyz","year":"2009","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0883073812450750","article-title":"Fatigue and depression in children with demyelinating disorders","volume":"28","author":"Parrish","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.23937","article-title":"Rasch analysis of clinical outcome measures in SMA","volume":"49","author":"Cano","year":"2014","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2019.03.012_bib60","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ejpn.2017.04.1218","article-title":"Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): interim results from the NURTURE study","volume":"21","author":"Bertini","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2019.03.012_bib62","series-title":"Muscle Disorders in Childhood","first-page":"325","article-title":"Disorders of the lower motor neurone: the spinal muscular atrophies","author":"Dubowitz","year":"1995"},{"key":"10.1016\/j.clinthera.2019.03.012_bib63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.clinthera.2019.03.012_bib64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26\u201328 june 1992, bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2019.03.012_bib65","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/0883073807305670","article-title":"Modern management of spinal muscular atrophy","volume":"22","author":"Iannaccone","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2019.03.012_bib66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-160168","article-title":"What matters most: a perspective from adult spinal muscular atrophy patients","volume":"3","author":"Hunter","year":"2016","journal-title":"J Neuromuscul. Dis."},{"key":"10.1016\/j.clinthera.2019.03.012_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1017\/S026646231200027X","article-title":"Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies","volume":"28","author":"Gallego","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clinthera.2019.03.012_bib68","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"Peay","year":"2014","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819301274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:52Z","timestamp":1758963052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819301274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0149291819301274"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}